Stanford's Virtual Biotech System Proposes B7-H3-Targeted Lung Cancer Therapy

Stanford University researchers developed a virtual biotech system with 37,000 AI agents that analyzed 37,075 clinical trials to propose a B7-H3-targeted lung cancer therapy using antibody-directed ch

Stanford University researchers developed a virtual biotech system with 37,000 AI agents to analyze drug targets and design therapies. The system processed 37,075 individual Phase II and III clinical trials to identify drug targets with 48% higher likelihood of reaching market, 40% higher likelihood of advancing from Phase 1 to Phase 2 trials, and 32% fewer adverse events compared to broadly active targets. It proposed a B7-H3-targeted lung cancer therapy using antibody-directed chemotherapy based on data available before January 2025.

The system uses the Open Targets database as a public repository and includes specialized agents for drug target validation, safety risk assessment, drug delivery design, and clinical trial data review. Its performance metrics apply specifically to switch-like genes active in limited cell types.

This approach could accelerate cancer treatment development by reducing trial failure rates and cutting time-to-market for novel therapies. However, the system is a simulation model—not an operational biotech company—and does not shorten clinical trial duration or lab testing requirements. A major pharmaceutical company independently achieved FDA breakthrough therapy status for ifinatamab deruxtecan in August 2025, but Stanford's system did not create or approve this therapy.

What to watch: The system's findings were validated using data available before January 2025, but its candidate selection process does not shorten clinical trial timelines. Performance benefits apply only to specific genetic targets, not all therapies.

Source: Singularity Hub